Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:BLTE NASDAQ:CNTA NASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$59.51+6.1%$60.37$11.40▼$72.36$1.63B0.72505,771 shs668,556 shsBLTEBelite Bio$144.24+4.4%$153.61$56.10▼$200.00$5.54B-1.24230,123 shs242,482 shsCNTACentessa Pharmaceuticals$39.76+0.1%$39.64$12.05▼$40.26$6.14B1.111.15 million shs1.61 million shsMIRMMirum Pharmaceuticals$101.00+1.7%$98.02$47.89▼$114.99$6.06B0.5678,885 shs832,595 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+6.14%+15.87%-5.76%-11.56%+155.19%BLTEBelite Bio+4.40%+3.30%+0.87%-10.64%+142.22%CNTACentessa Pharmaceuticals+0.10%+0.15%+0.43%+37.34%+221.16%MIRMMirum Pharmaceuticals+1.66%+7.93%-1.15%+4.61%+103.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$59.51+6.1%$60.37$11.40▼$72.36$1.63B0.72505,771 shs668,556 shsBLTEBelite Bio$144.24+4.4%$153.61$56.10▼$200.00$5.54B-1.24230,123 shs242,482 shsCNTACentessa Pharmaceuticals$39.76+0.1%$39.64$12.05▼$40.26$6.14B1.111.15 million shs1.61 million shsMIRMMirum Pharmaceuticals$101.00+1.7%$98.02$47.89▼$114.99$6.06B0.5678,885 shs832,595 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+6.14%+15.87%-5.76%-11.56%+155.19%BLTEBelite Bio+4.40%+3.30%+0.87%-10.64%+142.22%CNTACentessa Pharmaceuticals+0.10%+0.15%+0.43%+37.34%+221.16%MIRMMirum Pharmaceuticals+1.66%+7.93%-1.15%+4.61%+103.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.69Moderate Buy$81.8237.49% UpsideBLTEBelite Bio 2.63Moderate Buy$203.0040.74% UpsideCNTACentessa Pharmaceuticals 2.21Hold$41.333.96% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$139.8038.42% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, CNTA, MIRM, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/15/2026MIRMMirum Pharmaceuticals CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$146.006/15/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.006/15/2026MIRMMirum Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$140.00 ➝ $146.006/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.006/10/2026ANABAnaptysBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.006/8/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/2/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform ➝ Buy$145.006/1/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M7.38N/AN/A$1.34 per share44.41BLTEBelite BioN/AN/AN/AN/A$20.54 per shareN/ACNTACentessa Pharmaceuticals$15M409.95N/AN/A$3.92 per share10.14MIRMMirum Pharmaceuticals$521.31M11.81$0.05 per share1,948.74$6.12 per share16.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A18.31N/A-11.53%-1,101.24%-7.75%8/5/2026 (Estimated)BLTEBelite Bio-$77.61M-$2.53N/A119.21N/AN/A-13.14%-12.88%8/10/2026 (Estimated)CNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A439.13N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)Latest ANAB, CNTA, MIRM, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BLTEBelite Bio-$0.60-$0.34+$0.26-$0.68N/AN/A5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58BLTEBelite BioN/A33.7133.71CNTACentessa Pharmaceuticals0.239.539.53MIRMMirum Pharmaceuticals1.282.091.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ABLTEBelite Bio0.53%CNTACentessa Pharmaceuticals82.01%MIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%BLTEBelite Bio13.29%CNTACentessa Pharmaceuticals4.09%MIRMMirum Pharmaceuticals8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableBLTEBelite Bio1040.08 million34.76 millionNot OptionableCNTACentessa Pharmaceuticals200154.66 million148.34 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableANAB, CNTA, MIRM, and BLTE HeadlinesRecent News About These CompaniesMIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)1 hour ago | zacks.comMIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA ReviewJune 15 at 11:45 AM | zacks.comMirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Citizens Jmp Analyst SaysJune 15 at 10:20 AM | marketbeat.comMirum and Incyte's zilurgisertib shows positive Phase 2 data in FOPJune 15 at 9:05 AM | seekingalpha.comMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans ProgressivaJune 14 at 6:58 PM | finance.yahoo.comMirum Pharmaceuticals, Inc. $MIRM Holdings Cut by First Turn Management LLCJune 14 at 6:43 AM | marketbeat.comEventide Asset Management LLC Has $165.37 Million Stake in Mirum Pharmaceuticals, Inc. $MIRMJune 14 at 4:55 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Hinge Health, Inc. Class A (HNGE)June 13 at 8:52 AM | theglobeandmail.comRhenman & Partners Asset Management AB Has $8.39 Million Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRMJune 13 at 5:48 AM | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan StanleyJune 11, 2026 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $469,100.00 in StockJune 10, 2026 | insidertrades.comInsider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of StockJune 9, 2026 | marketbeat.comCenterBook Partners LP Purchases 37,010 Shares of Mirum Pharmaceuticals, Inc. $MIRMJune 9, 2026 | marketbeat.comMirum Pharmaceuticals, Inc. $MIRM Shares Sold by Clearbridge Investments LLCJune 9, 2026 | marketbeat.comGeode Capital Management LLC Has $83.98 Million Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRMJune 8, 2026 | marketbeat.comWhy Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?June 5, 2026 | zacks.comMirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL CongressJune 4, 2026 | finance.yahoo.comMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026June 4, 2026 | businesswire.comChristopher Peetz Sells 30,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockJune 3, 2026 | insidertrades.com47,630 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by Hillsdale Investment Management Inc.June 1, 2026 | marketbeat.comMirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026May 30, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026ANAB, CNTA, MIRM, and BLTE Company DescriptionsAnaptysBio NASDAQ:ANAB$59.51 +3.44 (+6.14%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$59.37 -0.14 (-0.24%) As of 06/15/2026 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Belite Bio NASDAQ:BLTE$144.24 +6.08 (+4.40%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$144.49 +0.25 (+0.17%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Centessa Pharmaceuticals NASDAQ:CNTA$39.76 +0.04 (+0.10%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$39.76 0.00 (0.00%) As of 06/15/2026 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Mirum Pharmaceuticals NASDAQ:MIRM$101.00 +1.65 (+1.66%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$101.60 +0.61 (+0.60%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
